Related Experiment Video
Updated: Jun 7, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Screening for pulmonary arterial hypertension in systemic sclerosis
1Pulmonary Hypertension and Heart Failure Clinic, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. jvachier@ulb.ac.be
Early screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) patients is vital. Current Doppler echocardiography methods require further research for optimal specificity and selectivity in PAH diagnosis.
Area of Science:
- Cardiology
- Rheumatology
- Pulmonology
Background:
- Pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) progresses aggressively.
- Early diagnosis and intervention are crucial for managing SSc-PAH.
- Accurate diagnosis can be challenging due to co-existing conditions causing breathlessness.
Purpose of the Study:
- To review current screening practices for PAH in SSc patients.
- To highlight the need for optimal screening tools and methodologies.
- To emphasize the importance of early detection and intervention.
Main Methods:
- Current practice involves annual Doppler echocardiography for SSc patients.
- Doppler echocardiography aims to detect elevated right heart pressures.
- Right heart catheterisation is the confirmatory diagnostic tool.
Main Results:
- Doppler echocardiography identifies most SSc patients with pulmonary hypertension.
- Optimal thresholds for echocardiography require further investigation.
- The technique may produce false-positives and false-negatives, especially in mild cases.
Conclusions:
- Annual screening of SSc patients with Doppler echocardiography is current practice.
- Further research is needed to determine optimal screening tools and methods.
- Improved specificity and selectivity in screening are essential for accurate PAH diagnosis in SSc.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
